Gold prices steady ahead of Fed decision; weekly weakness noted
In a challenging market environment, Cellectis (NASDAQ:CLLS) stock has reached a new 52-week low, dipping to $1.2. According to InvestingPro data, the company maintains a "GOOD" Financial Health score, with analysts setting price targets ranging from $3 to $10. This latest price level reflects a significant downturn for the biopharmaceutical company, which specializes in developing immunotherapies based on gene-edited T-cells. Over the past year, Cellectis has seen its stock value nearly halve, with a 1-year change showing a steep decline of 50.98%. Despite these challenges, the company shows promising fundamentals with strong revenue growth of 47% and maintains more cash than debt on its balance sheet. Investors are closely monitoring the company’s performance and potential catalysts that may influence its stock price in the coming months. InvestingPro analysis suggests the stock is currently undervalued, with additional insights available through their comprehensive Pro Research Report, which covers over 1,400 US stocks.
In other recent news, Cibus Inc. has successfully raised approximately $22.6 million through a registered direct offering. This transaction involved the sale of 9,040,000 shares of Class A common stock, including pre-funded warrants, at a price of $2.50 each. The offering is anticipated to close around January 24, 2025, subject to customary conditions. The company plans to use the net proceeds to advance its pipeline of productivity traits and meet general corporate needs. Additionally, amendments to existing investor warrants have been made, reducing their exercise price to $2.50 per share and extending their termination date. These changes will take effect upon the offering’s closure, with the exception of warrants held by CEO Rory Riggs, which require additional stockholder approval. A.G.P./Alliance Global Partners (NYSE:GLP) is serving as the sole placement agent for the offering. Cibus’s recent financial maneuvering reflects its ongoing efforts to secure long-term financing for its gene-editing technology projects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.